Attention-Based LSTM Network for COVID-19 Clinical Trial Parsing

12/18/2020
by   Xiong Liu, et al.
0

COVID-19 clinical trial design is a critical task in developing therapeutics for the prevention and treatment of COVID-19. In this study, we apply a deep learning approach to extract eligibility criteria variables from COVID-19 trials to enable quantitative analysis of trial design and optimization. Specifically, we train attention-based bidirectional Long Short-Term Memory (Att-BiLSTM) models and use the optimal model to extract entities (i.e., variables) from the eligibility criteria of COVID-19 trials. We compare the performance of Att-BiLSTM with traditional ontology-based method. The result on a benchmark dataset shows that Att-BiLSTM outperforms the ontology model. Att-BiLSTM achieves a precision of 0.942, recall of 0.810, and F1 of 0.871, while the ontology model only achieves a precision of 0.715, recall of 0.659, and F1 of 0.686. Our analyses demonstrate that Att-BiLSTM is an effective approach for characterizing patient populations in COVID-19 clinical trials.

READ FULL TEXT
research
05/19/2023

AutoTrial: Prompting Language Models for Clinical Trial Design

Clinical trials are critical for drug development. Constructing the appr...
research
09/14/2023

Text Classification of Cancer Clinical Trial Eligibility Criteria

Automatic identification of clinical trials for which a patient is eligi...
research
05/25/2021

Impact of detecting clinical trial elements in exploration of COVID-19 literature

The COVID-19 pandemic has driven ever-greater demand for tools which ena...
research
04/14/2023

Improving Patient Pre-screening for Clinical Trials: Assisting Physicians with Large Language Models

Physicians considering clinical trials for their patients are met with t...
research
10/12/2020

Predicting Clinical Trial Results by Implicit Evidence Integration

Clinical trials provide essential guidance for practicing Evidence-Based...
research
02/14/2012

Active Learning for Developing Personalized Treatment

The personalization of treatment via bio-markers and other risk categori...

Please sign up or login with your details

Forgot password? Click here to reset